For Faster Cures
Cancer, Parkinsons, Multiple Sclerosis, Zika. The list of deadly diseases and viruses that continue to challenge the scientific and medical community goes on. But PerkinElmer's latest technology is helping researchers go further. Our imaging solutions are allowing them to better visualize and understand cellular activity, phenotypes and drug treatments. Other applications of our disease research solutions include identifying staph infections, detecting dementia, and studying the effect of stem cells on neurotrauma.
Cytotoxic T cells (CTCs) are natural-born killers that seek out and destroy cancer cells. Unfortunately, cancer cells have their own countermeasures…
When three different dogs underwent surgery to remove cancerous tumors, little did they know they were part of a research breakthrough…
Neuroscientists successfully isolated in a petri dish oligodendrocyte progenitor cells, which aid in protecting the central nervous system from MS…
Our fully automated quantitative pathology system integrates both multispectral imaging and automated slide scanning to better visualize, quantify, and phenotype immune cells in situ in FFPE tissue sections and TMAs. Coupled with the power of inForm® image analysis software, Vectra Polaris allows easy detection and measurement of multiple overlapping biomarkers within a single tissue section.
The premier confocal solution for today's most demanding high content applications. Drawing on over a decade of experience with the industry-leading Opera® High Content Screening System, the Opera Phenix is designed for high-throughput, phenotypic screening and assays involving complex disease models, such as live cells, primary cells and microtissues.
Innovation in Cancer Immunology
Whether it’s making new drugs or testing what’s happening in the actual population. This is a first. Future studies using Single Cell ICP-MS will allow researchers to better understand metal uptake in cancer cells that will likely lead to new therapies not only for the treatment of ovarian cancer, but for a number of other cancers treated with metal based drugs.Dr. Lauren Amable from the NIH shares her insights and what it means for the future of cancer treatments